Oncology pharmacy Onco360 stated on Friday that it will market TAZVERIK (Tazemetostat) for treatment of patients with epithelioid sarcoma under the exclusive specialty pharmacy partnership with Epizyme.

Epizyme added that TAZVERIK (Tazemetostat) is a FDA approved new oral treatment for adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

Epithelioid sarcoma is a rare, slow-growing subtype of soft tissue sarcoma which occurs primarily in young adults. Greater than 90% of epithelioid sarcoma patients are found to have a genetic mutation, known as loss of INI-1 function, rendering them amenable to treatment with TAZVERIK, a novel EZH2 inhibitor.

In conjunction, TAZVERIK is manufactured by Epizyme, a research-based biotechnology company.

US FDA approval of TAZVERIK is based on the results from Epizyme's open-label, single-arm cohort of patients from the Phase II EZH-202 clinical trial (NCT02601950), which demonstrated a 15% overall rate of response.